Answers are grounded in this paper and cite their sources.
To our knowledge, this analysis represents the first characterization of the activity and pharmacokinetics of mirdametinib in patients with NF1 and PNs and is the first published response study for MAPK/ERK kinase inhibitors in adults with NF1 and PNs. Mirdametinib given at 2 mg/m²/dose (maximum dose, 4 mg) twice daily in a 3-week on/1-week off sequence resulted in a 42% partial response rate with preliminary evidence of reduction in pain.
No takes yet. Share an insight, caveat, or question.
Weiss et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: